STAT

STAT

January 2, 2020 Alex Hogan/STAT G ood morning, everyone, and welcome to a new year. We hope the extended respite — for those of you who were able to enjoy — was refreshing and relaxing, because the inevitable routine has unsurprisingly returned. So please join us as we hoist a cup of stimulation to a year of fresh challenges that await. Meanwhile, here are some tidbits to help you ease in. Hope your day goes well and you find it manageable. Newly unearthed documents show the Food and Drug Administration failed to use its policing powers to make sure a program to curb improper prescribing of opioids was effective , The New York Times writes, citing research in JAMA. In 2011, the FDA asked the makers of OxyContin and other addictive long-acting opioids to pay for safety training for more than half the physicians prescribing the drugs, and to track the effectiveness of the training and other measures in reducing addiction, overdoses, and deaths. But the FDA was never able to determine whether the program worked Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months! Log In | Learn More What is it? STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What's included? The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day Online intelligence briefings Frequent opportunities to engage with veteran beat reporters and industry experts Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More